New SPIRIVA(R) Respimat(R) Inhaler Completes European Approval Process for COPD (y 2)

    
    Contact:
    Boehringer Ingelheim GmbH
    Ute E Schmidt
    Corporate Division Communications
    55216 Ingelheim am Rhein
    GERMANY
    Phone: +49-6132-77-97296
    Pfizer Inc
    Francisco Gebauer
    Corporate Media Relations
    235 East 42nd street
    New, York, NY
    USA
    Phone: +1-212-733-5191

Graphics, photos and data for feature articles are available on request.

References

-- (1) Hydrofluoroalkane Metered Dose Inhaler, Turbuhaler(R), Diskus(R)

-- (1) Data on file. Ingelheim, Germany: Boehringer Ingelheim International GmbH.

-- (2) Hodder R. Design and interpretation of device preference trials: marketing tools or scientific instruments? Respiratory Drug Delivery. 2006;1:19-36.

-- (3) Schürmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat(R) Soft Mist (TM) Inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4:53-61.

-- (4) Hodder R, Reese PR. Asthma patients prefer Respimat(R) Soft Mist(TM) Inhaler to Turbuhaler(R). Presented at: International Society for Aerosols in Medicine (ISAM) 16th Congress; June 16-20, 2007; Tours, France.

-- (5) Freytag F, Rau-Berger H, Glaab T, Wolf K. Respimat(R) Soft Mist (TM) Inhaler preferred to Diskus by patients with COPD and/or asthma. Presented at: 2007 International Conference of the American Thoracic Society (ATS); May 18-23, 2007; San Francisco, CA.

-- (6) Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.

-- (7) Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.

-- (8) IMS Health, IMS MIDAS(tm), 2Q2005

-- (9) Giraud V et al. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J.2002;19:246-251

-- (10) World Health Organization. World Health Report 2004. Statistical Annex. Annex table 2 and 3: 120-131.

-- (11) Murray CJL, Lopez AD. eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge; Harvard University Press; 1996.

-- (12) Centers for Disease Control and Prevention. Surveillance Summaries, August 2, 2002. MMWR: 51 (No SS06). http://www.cdc.gov/mmwr

-- (13) Rudolf M. The reality of drug use in COPD: The European Perspective. Chest 2000; 117(suppl): 29S-32S.

-- (14) van Noord JA, Cornelissen G, Aumann J-L, Platz J, Mueller A, Fogarty C. Efficacy in COPD patients of tiotropium administered via the Respimat(R) Soft Mist(TM) Inhaler (SMI) compared to HandiHaler(R) (HH) Eur. Respir. J 2006; 28 (suppl 50): 431S

-- (15) Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748.

-- (16) Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.

-- (17) O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J.2004 23(6):832-48

-- (18) Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.

-- (19) Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128:1168-1178.

-- (20) Pocket Guide to COPD diagnosis, management, and prevention - A guide for healthcare professionals. Global Initiative for Chronic Obstructive Lung Disease. Available at: http://www.goldcopd.com

Contact: Boehringer Ingelheim GmbH, Ute E Schmidt, Corporate Division Communications, 55216 Ingelheim am Rhein, GERMANY, Phone: +49-6132-77-97296; Pfizer Inc, Francisco Gebauer, Corporate Media Relations, 235 East 42nd street, New, York, NY, USA, Phone: +1-212-733-5191